clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
Published 1 year ago • 466 plays • Length 2:14Download video MP4
Download video MP3
Similar videos
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:33
questions remaining in the field of her2-low breast cancer
-
6:51
adcs for her2 and her2-low breast cancer
-
3:08
the molecular differences between younger versus older er-positive and her2-negative breast cancers
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
2:05
latest news in her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
0:35
key challenge associated with the management of hr /her2- breast cancer
-
2:46
de-escalation of therapy in early-stage tnbc
-
2:30
prognostic value of her2-low status in breast cancer: a systematic review and meta-analysis
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
55:01
advances in treatment of triple-negative breast cancer: a success story
-
0:52
defining her2-low breast cancer as a clinical subtype
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:36
is her2-low a distinct subtype of breast cancer?
-
7:13
overview of the management of her2-low breast cancer patients
-
1:09
the exciting new field of her2-low breast cancer